ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
Cancers · 26.02.2024 · 16 (5) · 940
DOI: 10.3390/cancers16050940 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.02.2024. Verfasst von Aakash Desai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb Foundation.
Abstract (Originalsprache)
Circulating tumor DNA (ctDNA) offers a new paradigm in optimizing treatment strategies for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Its potential spans early-stage disease, influencing adjuvant therapy, to advanced disease, where it aids in identifying genomic markers and resistance mechanisms. This review explores the evolving landscape of utilizing liquid biopsies, specifically circulating tumor DNA (ctDNA), in the management of NSCLC with EGFR mutations. While tissue-based genomic testing remains the cornerstone for clinical decision-making, liquid biopsies offer a well-validated, guideline-recommended alternative approach. Ongoing trials integrating ctDNA for EGFR-mutant NSCLC management are also discussed, shedding light on the potential of ctDNA in early-stage disease, including its applications in prognostication, risk stratification, and minimal residual disease detection post-curative intent treatment. For advanced disease, the role of ctDNA in identifying resistance mechanisms to EGFR tyrosine kinase inhibitors (TKIs) is explored, providing insights into disease progression and guiding treatment decisions. This review also addresses the challenges, including the limitations in sensitivity of current assays for disease recurrence detection, and calls for future studies to refine treatment approaches, standardize reporting, and explore alternative biofluids for enhanced sensitivity. A systematic approach is crucial to address barriers to ctDNA deployment, ensuring equitable access, and facilitating its integration into routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
- School of Medicine, Ponce Health Sciences University, Ponce, PR 00716, USA.
- Thoracic Oncology Unit, BP-A Beneficência Portuguesa de São Paulo, São Paulo 01323-001, Brazil.
- Center for Thoracic Oncology, The Tisch Cancer Institute, Mount Sinai Health System, New York, NY 10029, USA.
- Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
- Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA.
ORCID-Profile: Aakash Desai, Tadana A Vázquez, Marcelo Corassa, Bruna Pellini
Förderung
- Bristol Myers Squibb Foundation
Zitieren
APA
Desai, A., Vázquez, T. A., Arce, K. M., Corassa, M., Mack, P. C., Gray, J. E., & Pellini, B. (2024). ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer. Cancers, 16(5), 940. https://doi.org/10.3390/cancers16050940
Vancouver
Desai A, Vázquez TA, Arce KM, Corassa M, Mack PC, Gray JE, et al. ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer. Cancers. 2024;16(5):940. doi:10.3390/cancers16050940
BibTeX
@article{Desai2024,
author = {Desai, Aakash and Vázquez, Tadana A and Arce, Keishla M and Corassa, Marcelo and Mack, Philip C and Gray, Jhanelle E and Pellini, Bruna},
title = {ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {5},
pages = {940},
doi = {10.3390/cancers16050940}
}
EUVIMED